The postmenopausal osteoporosis refers to a reduction in bone mass and density that occurs after menopause due to declining estrogen levels. It often goes undetected until a sudden bone fracture occurs. Postmenopausal osteoporosis drugs aim to rebuild and protect bone tissue by increasing bone mineral density and decreasing bone resorption.
The global postmenopausal osteoporosis market is estimated to be valued at US$ 4747.9 Mn in 2023 and is expected to exhibit a CAGR of 67.% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
Rising demand for osteoporosis drugs: The rising demand for osteoporosis drugs across the world owing to the growing geriatric population affected by postmenopausal osteoporosis is one of the major factors fueling the growth of this market. As per estimates, over 200 million people suffer from osteoporosis globally. Moreover, widespread promotion and awareness campaigns regarding postmenopausal osteoporosis and the benefits of its treatment are also encouraging the use of osteoporosis medications in postmenopausal women. This growing demand is expected to continue fuelling market revenue growth over the forecast period.
SWOT Analysis
Strength: Drugs and treatments available for postmenopausal osteoporosis have improved considerably offering better efficacy and safety. Advances in treatment are expected to further drive the market growth.
Weakness: High cost of osteoporosis treatment and drugs remains a challenge for many patients. Lack of awareness about osteoporosis in developing regions also limit market growth.
Opportunity: Emerging economies with aging population present significant growth opportunities for osteoporosis drugs manufacturers. Development of personalized treatment approaches may further boost the market.
Threats: Patent expiry of blockbuster drugs will increase generic competition and pricing pressure. Stringent regulations for new drug approvals also restrict market growth.
Key Takeaways
Global Postmenopausal Osteoporosis Market Size is expected to witness high growth. Advancements in treatment options along with several drugs in the pipeline are anticipated to drive robust market expansion through 2030.
Regional analysis: North America currently dominates the market and is expected to continue its leading position over the forecast period. This is attributed to growing geriatric population, awareness levels, and new product launches. However, Asia Pacific region is likely to emerge as the fastest-growing market owing to increasing healthcare spending and growing prevalence of osteoporosis among aging women population.
Key players operating in the postmenopausal osteoporosis market are IBM Research, Inc., Knowm Inc., Intel Corp., BrainChip Holdings Ltd., General Vision Inc., HRL Laboratories, LLC, Qualcomm Technologies Inc., and Hewlett Packard Labs. These players are focusing on developing novel therapeutics and creating strategic collaborations for market expansion.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it